Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s stock price rose 7.7% during mid-day trading on Monday . The stock traded as high as $9.97 and last traded at $9.91. Approximately 124,881 shares were traded during trading, a decline of 75% from the average daily volume of 493,136 shares. The stock had previously closed at $9.20.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on PRTA. Royal Bank of Canada lowered their target price on Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Friday, February 21st. StockNews.com upgraded Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a report on Friday, February 21st. Piper Sandler lifted their price objective on Prothena from $94.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Oppenheimer increased their price target on shares of Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research note on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $55.00.
Check Out Our Latest Analysis on PRTA
Prothena Trading Up 0.5 %
The firm has a 50-day moving average of $12.45 and a two-hundred day moving average of $14.18. The firm has a market cap of $522.12 million, a price-to-earnings ratio of -4.22 and a beta of 0.07.
Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The business had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million. As a group, equities analysts anticipate that Prothena Co. plc will post -4.04 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its stake in shares of Prothena by 110.2% during the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company's stock valued at $1,592,000 after purchasing an additional 49,916 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Prothena by 167.0% during the fourth quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company's stock worth $521,000 after purchasing an additional 23,525 shares during the last quarter. Duncan Williams Asset Management LLC raised its stake in shares of Prothena by 41.9% during the 4th quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company's stock worth $958,000 after purchasing an additional 20,450 shares during the period. Rhumbline Advisers increased its position in Prothena by 1.8% in the fourth quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock worth $930,000 after buying an additional 1,175 shares during the last quarter. Finally, Focused Wealth Management Inc bought a new stake in shares of Prothena in the fourth quarter valued at approximately $445,000. Institutional investors own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Recommended Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
